Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Payables (2019 - 2025)

Historic Payables for AVITA Medical (RCEL) over the last 7 years, with Q3 2025 value amounting to $8.1 million.

  • AVITA Medical's Payables rose 9362.31% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year increase of 9362.31%. This contributed to the annual value of $3.8 million for FY2023, which is 2634.91% up from last year.
  • Latest data reveals that AVITA Medical reported Payables of $8.1 million as of Q3 2025, which was up 9362.31% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, AVITA Medical's Payables ranged from a high of $8.7 million in Q1 2025 and a low of $2.4 million during Q1 2022
  • Moreover, its 5-year median value for Payables was $3.7 million (2021), whereas its average is $4.1 million.
  • As far as peak fluctuations go, AVITA Medical's Payables tumbled by 3411.21% in 2022, and later skyrocketed by 9381.28% in 2025.
  • Quarter analysis of 5 years shows AVITA Medical's Payables stood at $2.7 million in 2021, then increased by 10.86% to $3.0 million in 2022, then rose by 26.35% to $3.8 million in 2023, then increased by 10.39% to $4.2 million in 2024, then soared by 93.62% to $8.1 million in 2025.
  • Its Payables was $8.1 million in Q3 2025, compared to $7.3 million in Q2 2025 and $8.7 million in Q1 2025.